Improvements in diagnostic modalities have increased the prevalence of somatotroph adenomas through the identification of active acromegaly (high IGF-1 and/or GH levels) in clinically asymptomatic patients, also called silent somatotroph adenomas [3]. The gene discussed is GH1; the disease is growth hormone secreting pituitary adenoma 1.